FCM
APLS

Frontier Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Frontier Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-77,561
Closed -$2.98M – 284
2024
Q2 		$2.98M Sell
77,561
-487
-0.6% -$22.1K 0.03% 261
2024
Q1 		$4.59M Buy
+78,048
New +$4.98M 0.04% 252
2023
Q4 		– Sell
-34,600
Closed -$1.32M – 264
2023
Q3 		$1.32M Buy
+34,600
New +$1.52M 0.01% 255
2022
Q4 		– Sell
-6,193
Closed -$423K – 264
2022
Q3 		$423K Buy
6,193
+133
+2% +$7.87K 0.01% 265
2022
Q2 		$274K Sell
6,060
-9,489
-61% -$433K ﹤0.01% 274
2022
Q1 		$790K Sell
15,549
-107,941
-87% -$4.77M 0.01% 265
2021
Q4 		$5.84M Sell
123,490
-152,420
-55% -$6M 0.05% 249
2021
Q3 		$9.09M Buy
275,910
+98,385
+55% +$5.53M 0.07% 225
2021
Q2 		$11.2M Buy
+177,525
New +$9.16M 0.08% 227

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Frontier Capital Management's APLS Position: Q3 2024 in Review

Frontier Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 77,561 shares — an estimated $2.98M sold.

Frontier Capital Management first reported a position in APLS in Q2 2021 and held it in 9 quarters. The position peaked at $11.2M in Q2 2021. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Frontier Capital Management reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Frontier Capital Management sold 77,561 Apellis Pharmaceuticals shares in Q3 2024, an estimated $2.98M.
  • Frontier Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • Frontier Capital Management's Apellis Pharmaceuticals position peaked at $11.2M in Q2 2021.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Frontier Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.